VBI Vaccines Inc. (NASDAQ:VBIV) announced positive top-line data from its Phase III PROTECT trial comparing its Sci-B-Vac trivalent hepatitis B vaccine to GlaxoSmithKline’s Engerix-B vaccine. The trial found …
Tag: India Globalization Capital
VBI Vaccines Inc. (NASDAQ:VBIV) announced positive top-line data from its Phase III PROTECT trial comparing its Sci-B-Vac trivalent hepatitis B vaccine to GlaxoSmithKline’s Engerix-B vaccine. The trial found …